Petros Pharmaceuticals, Inc.
PTPI
$0.0579
$0.00397.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 299.12% | -5.87% | -28.71% | -44.85% | -145.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 299.12% | -5.87% | -28.71% | -44.85% | -145.65% |
| Cost of Revenue | 67.49% | -29.74% | -35.96% | -39.75% | -82.06% |
| Gross Profit | 188.17% | 1.83% | -26.20% | -46.27% | -527.88% |
| SG&A Expenses | -49.65% | 14.96% | 1.64% | 27.26% | -1.52% |
| Depreciation & Amortization | -18.25% | -10.57% | -13.18% | -13.18% | -12.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.11% | 7.99% | -16.93% | 38.93% | -4.59% |
| Operating Income | 65.33% | -19.89% | 7.39% | -200.03% | -22.86% |
| Income Before Tax | -3,014.33% | 51.19% | 74.01% | -56.14% | 107.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,014.33% | 51.19% | 74.01% | -56.14% | 107.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,014.33% | 51.19% | 74.01% | -56.14% | 107.54% |
| EBIT | 65.33% | -19.89% | 7.39% | -200.03% | -22.86% |
| EBITDA | 74.24% | -42.27% | 4.46% | -565.37% | -33.01% |
| EPS Basic | 33.91% | 81.28% | 69.22% | -154.43% | 20.60% |
| Normalized Basic EPS | -566.51% | 89.47% | 92.55% | 31.46% | 106.56% |
| EPS Diluted | 33.91% | 81.28% | 69.22% | -154.43% | 20.60% |
| Normalized Diluted EPS | -566.51% | 89.47% | 92.55% | 31.46% | 106.56% |
| Average Basic Shares Outstanding | 325.10% | 363.76% | 248.89% | 127.75% | 14.57% |
| Average Diluted Shares Outstanding | 325.10% | 363.76% | 248.89% | 127.75% | 14.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |